A multicenter study of clinical usefulness of flow-mediated vasodilation B

Conditions

Patients with hypertension or diabetes mellitus

Yamaji T, Yusoff FM, Kishimoto S, Kajikawa M, Harada T, Mizobuchi A, Maruhashi T, Nakashima A, Tomiyama H, Higashi Y.

2024-12-05

10.1038/s41440-024-02029-3

Association of cumulative low-density lipoprotein cholesterol exposure with vascular function.

Yamaji T, Yusoff FM, Kishimoto S, Kajikawa M, Yoshimura K, Nakano Y, Goto C, Harada T, Mizobuchi A, Tanigawa S, Maruhashi T, Higashi Y.

2023-12-256 citations

10.1016/j.jacl.2023.12.006

Inconvenient relationship of haemoglobin A1c level with endothelial function in type 2 diabetes in a cross-sectional study

Takayuki Yamaji, Takahiro Harada, Yu Hashimoto, Yuji Takaeko, Masato Kajikawa et al. (16 authors)

BMJ Open2021-06-016 citations

10.1136/bmjopen-2020-045415

Pre-impaired fasting glucose state is a risk factor for endothelial dysfunction: Flow-mediated Dilation Japan (FMD-J) study

Takayuki Yamaji, Takahiro Harada, Yu Hashimoto, Yuji Takaeko, Masato Kajikawa et al. (15 authors)

BMJ Open Diabetes Research & Care2020-10-0119 citations

10.1136/bmjdrc-2020-001610

Diagnostic Criteria of Flow‐Mediated Vasodilation for Normal Endothelial Function and Nitroglycerin‐Induced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery

Tatsuya Maruhashi, Masato Kajikawa, Shinji Kishimoto, Haruki Hashimoto, Yuji Takaeko et al. (39 authors)

Journal of the American Heart Association2020-01-08122 citations

10.1161/jaha.119.013915

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Enrolled patients are those with hypertension or diabetes mellitus, whose conditions are being well-controled with treatment (ie, blood pressure of <150/95 mmHg and HbA1c level of <7.5%), and who have been receiving follow-up at 1 of the participating centers for at least 6 months.

Exclusion criteria

Exclusion criteria: The exclusion criteria are: the presence of coronary artery disease, including a history of percutaneous coronary intervention or coronary bypass surgery; severe valvular heart disease; arrhythmia requiring treatment (ie, atrial fibrillation, atrial flutter, permanent pacemaker implantation or frequent ventricular premature beats); impaired left ventricular systolic function (left ventricular ejection fraction of <40%); malignancy; receiving treatment with steroids, nonsteroidal anti-inflammatory drugs or immunosuppressive drugs; a serum creatinine level of greater than 2.5 mg/dL; stroke or aortic disease (except peripheral artery disease) and serious liver disease.

Design outcomes

Primary

Measure	Time frame
1) Ultrasound examination of the carotid artery: max intima-media thickness (IMT), mean IMT. 2) Urinary microalbumin and creatinine excretion measurements.	—

Secondary

Measure	Time frame
Ultrasound examination of the carotid artery: plaque score	—

Countries

Japan

Contacts

Public ContactYukihito Higashi

Research Institute for Radiation Biology and Medicine 1

yhigashi@hiroshima-u.ac.jp082-257-5831

Outcome results